

Being a Navy SEAL is one of the most physically and mentally difficult jobs in the world. The SEALs' training is legendary for its toughness. Their missions are dangerous and secret. They work in small teams, on the frontlines of war. Only the best of the best can serve as Seals, and Shane Patton did it with honor and distinction.

In Afghanistan, Shane died during a combat mission. He was buried last Saturday at the Southern Nevada Veterans Cemetery in Boulder City. He now rests among other Nevada heroes—brave men and women who dedicated part of their lives to protecting and preserving the freedoms we hold dear. I attended Shane's funeral and extended the appreciation of a grateful Nation.

A year from now Boulder City will again celebrate the Fourth of July. As is tradition, people from all over will journey back to the city they used to call home. Shane Patton will not be there. But he will live on in the hearts and minds of everyone in Boulder City and in everyone who pauses to remember the freedoms we enjoy.

Shane's life's work was keeping us safe. His service was his gift to us all. And his sacrifice will never be forgotten.

LANCE CORPORAL THOMAS WILLIAM FRITSCH

Mr. LIEBERMAN. Mr. President, I rise today to pay tribute to LCpl Thomas William Fritsch, U.S. Marines, of Cromwell, CT. Lance Corporal Fritsch lived as a true patriot and defender of our great Nation's principles of freedom and justice.

While serving during the Vietnam War, a group of marines from Battery D, including Lance Corporal Fritsch, was assigned to search for Sergeant Miller and medic Thomas Perry. The search had become necessary when it was apparent that the medic was missing during the evacuation of the base at Ngok Tavak which had come under enemy attack early on the morning of the 10th of May, 1968. It was during the course of this search when the small group was attacked by enemy fire.

Although it has been 37 years since his loss, his repatriation serves as a testament to our Nation's commitment to our Prisoners of War, those Missing in Action, and their families. I commend the Department of Defense Prisoner of War and Missing Personnel Office for their remarkable and tireless efforts during their numerous investigations which have once again been successful in identifying one of our Nation's heroes. I can only imagine the range of emotions caused by the loss and years of uncertainty experienced by Lance Corporal Fritsch's family, as well as other families of our servicemen missing in action.

In addition to his family, there are many in Connecticut who still remember him fondly. As a 1966 graduate of the EC Goodwin Technical-Vocational School in New Britain, CT, he is remembered as a good friend, a good neighbor, and an active member of the community who enjoyed volunteering

for the Portland Fire Department and participating in the Boy Scouts. Perhaps, Lance Corporal Fritsch will most be remembered as an aspiring chef as his former guidance counselor, Jane Rich, vividly recalls.

Lance Corporal Fritsch will soon be laid to rest at Rose Hill Cemetery in Rocky Hill. Lance Corporal Fritsch lives on through his parents, William and Mary, and his siblings, Patricia, Gloria, Bill and Steve whom I thank for his patriotic service.

Our Nation extends its heartfelt condolences to his family. We extend our appreciation for sharing this outstanding marine with us, and hope that they may find peace and closure. They may be justifiably proud of his contributions.

#### CONTROLLED SUBSTANCES IMPORT AND EXPORT ACT OF 2005

Mr. HATCH. Mr. President, I rise to speak of the Controlled Substances Export Reform Act of 2005. This bill would make a minor, but long overdue, change to the Controlled Substances Act to reflect the reality of commerce in the 21st Century and to protect high-paying American jobs, while maintaining strong safeguards on exports.

Before I discuss this bill, I want to thank Senator BIDEN for working with me on this important legislation. Senator BIDEN has long been recognized as a national leader on drug-related measures, and we have a history of working together on a bipartisan basis to enact sensible reforms in this area, as evidenced by the recent enactment of our steroid precursor bill. I respect his thoughtful collaboration, and I thank him for his work on this proposal.

I would also like to thank Chairman SPECTER for his critical work on this legislation. We would not be able to move this important bill without his efforts. Furthermore, I would like to thank the majority leader for moving this legislation during the last Congress. We were able to pass the measure last fall, and I hope that we may do so again in the near future.

This Hatch-Biden bill has been my priority for a number of years. The need for this legislation was first brought to my attention by a number of Utah companies, who had experienced significant difficulties in exporting their pharmaceutical products.

Under current law, there are two differing regulatory schemes governing export of U.S.-manufactured pharmaceutical products. One system, adopted by the Congress 10 years ago, governs products regulated under the Federal Food, Drug and Cosmetic Act. The other, which we are today proposing to harmonize with the food and drug law, governs pharmaceuticals with abuse potential regulated under the Controlled Substances Act. In sum, our proposed legislation amends the Controlled Substances Act to allow greater opportunities for U.S. manufacturers to send their products abroad, still re-

taining full Drug Enforcement Administration authority over those exports.

At present, U.S. pharmaceutical manufacturers are permitted to export most controlled substances only to the immediate country where the products will be consumed. Shipments to centralized sites for further distribution across national boundaries are prohibited, even though this same system is allowed under the Federal Food, Drug and Cosmetic Act for products which are not controlled substances. The current system for export of controlled substances should be contrasted with the freedom of pharmaceutical manufacturers throughout the rest of the world to readily move approved medical products among and between international drug control treaty countries without limitation or restriction.

The unique prohibitions imposed on domestic manufacturers disadvantage U.S. businesses by requiring smaller, more frequent and costly shipments to each country of use without any demonstrable benefit to public health or safety. By imposing significant logistical challenges and financial burdens on U.S. companies, the law creates a strong incentive for domestic pharmaceutical manufacturers to move production operations overseas, threatening high-wage American jobs.

The Controlled Substances Act of 1970 permits U.S. manufacturers of Schedule I and II substances and Schedule III and IV narcotics to export their products from U.S. manufacturing sites only to the receiving country where the drug will be used. The law prohibits export of these products if the drugs are to be distributed outside the country to which they are initially sent. The effect of this restriction is to prevent American businesses from using cost-effective, centralized foreign distribution facilities. In addition, under the current regime, unexpected cross-border demands or surges in patient needs cannot be met. Likewise, complex and time-sensitive export licensing procedures prevent the shipment of pharmaceuticals on a real time basis.

European drug manufacturers face no such constraints. They are able to freely move their exported products from one nation to another while complying with host country laws. This is entirely consistent with the scheme of regulation imposed by international drug control treaties. Only the United States imposes the additional limitation of prohibiting the further transfer of controlled substances. Thus, while a French or British company can ship its products to a central warehouse in Germany for subsequent distribution across the European Union, an American company must incur the added costs of shipping its products separately to each individual country.

S. 1395, the Controlled Substances Export Reform Act, would correct this imbalance and permit the highly-regulated transshipment of exported pharmaceuticals placing American businesses on an equal footing with the

rest of the world. Importantly, however, DEA's authority to control U.S. exports would not be diminished.

The legislation authorizes the Attorney General, or his designee, the DEA, to permit the re-export of Schedule I and II substances and Schedule III and IV narcotics to countries that are parties to the Single Convention on Narcotic Drugs and the Convention on Psychotropic Substances under tightly controlled circumstances: First, each country is required to have an established system of controls deemed adequate by the DEA. Next, only permit or license holders in those countries may receive regulated products. Third, re-exports are limited to one single cross-border transfer. Then the DEA must be satisfied by substantial evidence that the exported substance will be used to meet an actual medical, scientific or other legitimate need, and that the second country of receipt will hold or issue appropriate import licenses or permits. Fifth, in addition, the exporter must notify the DEA in writing within 30 days of a re-export. And finally, an export permit must have been issued by the DEA.

These safeguards are rigorous but fair, and represent a much-needed modernization of the law. The current restrictions on U.S. exports of controlled substances have remained essentially unchanged for more than 30 years. In that time, the global economy has changed dramatically. For those among us who express concerns about the outsourcing of American jobs and the competitiveness of U.S. companies, this modest change represents an opportunity to address such problems head-on.

The Controlled Substance Act's limitation on U.S. pharmaceutical exports imposes unique, unnecessary, and significant logistical and financial burdens on American businesses. The effect of this outdated policy is to create a strong incentive for domestic pharmaceutical companies to move production overseas, threatening American jobs and eliminating DEA jurisdiction over the manufacture and shipment of their products. The Controlled Substances Export Reform Act removes this unwarranted barrier to U.S. manufacturers' use of cost-effective distribution techniques while retaining full DEA control of U.S. exports and re-exports. Accordingly, I urge my colleagues to join Senator BIDEN and myself in support of this bill.

#### RULES OF THE SENATE COMMITTEE ON THE JUDICIARY

Mr. SPECTER. Mr. President, I ask unanimous consent that the Committee Rules approved by the Senate Committee on the Judiciary be included in the RECORD for today, July 14, 2005.

#### RULES OF THE SENATE COMMITTEE ON THE JUDICIARY

##### I. MEETINGS OF THE COMMITTEE

1. Meetings of the Committee may be called by the Chairman as he may deem nec-

essary on three days' notice of the date, time, place and subject matter of the meeting, or in the alternative with the consent of the Ranking Minority Member, or pursuant to the provision of the Standing Rules of the Senate, as amended.

2. Unless otherwise called pursuant to (1) of this section, Committee meetings shall take place promptly at 9:30 AM each Thursday the Senate is in session.

3. At the request of any Member, or by action of the Chairman, a bill, matter, or nomination on the agenda of the Committee may be held over until the next meeting of the Committee or for one week, whichever occurs later.

##### II. HEARINGS OF THE COMMITTEE

1. The Committee shall provide a public announcement of the date, time, place and subject matter of any hearing to be conducted by the Committee or any Subcommittee at least seven calendar days prior to the commencement of that hearing, unless the Chairman with the consent of the Ranking Minority Member determines that good cause exists to begin such hearing at an earlier date. Witnesses shall provide a written statement of their testimony and curriculum vitae to the Committee at least 24 hours preceding the hearing testimony in as many copies as the Chairman of the Committee or Subcommittee prescribes.

2. In the event 14 calendar days' notice of a hearing has been made, any witness appearing before the Committee, including any witness representing a Government agency, must file with the Committee at least 48 hours preceding her appearance a written statement of her testimony and curriculum vitae in as many copies as the Chairman of the Committee or Subcommittee prescribes. In the event the witness fails to file a written statement in accordance with this rule, the Chairman may permit the witness to testify, or deny the witness the privilege of testifying before the Committee, or permit the witness to testify in response to questions from Senators without the benefit of giving an opening statement.

##### III. QUORUMS

1. One-third of the membership of the Committee, actually present, shall constitute a quorum for the purpose of discussing business. Eight members of the Committee, including at least two members of the minority, must be present to transact business. No bill, matter, or nomination shall be ordered reported from the Committee, however, unless a majority of the Committee is actually present at the time such action is taken and a majority of those present support the action taken.

2. For the purpose of taking sworn testimony, a quorum of the Committee and each Subcommittee thereof, now or hereafter appointed, shall consist of one Senator.

##### IV. BRINGING A MATTER TO A VOTE

1. The Chairman shall entertain a non-debatable motion to bring a matter before the Committee to a vote. If there is objection to bring the matter to a vote without further debate, a roll call vote of the Committee shall be taken, and debate shall be terminated if the motion to bring the matter to a vote without further debate passes with ten votes in the affirmative, one of which must be cast by the minority.

##### V. AMENDMENTS

1. Provided at least seven calendar days' notice of the agenda is given, and the text of the proposed bill or resolution has been made available at least seven calendar days in advance, it shall not be in order for the Committee to consider any amendment in the first degree proposed to any measure under consideration by the Committee unless such

amendment has been delivered to the office of the Committee and circulated via e-mail to each of the offices by at least 5:00 PM the day prior to the scheduled start of the meeting.

2. It shall be in order, without prior notice, for a Member to offer a motion to strike a single section of any bill, resolution, or amendment under consideration.

3. The time limit imposed on the filing of amendments shall apply to no more than three bills identified by the Chairman and included on the Committee's legislative agenda.

4. This section of the rule may be waived by agreement of the Chairman and the Ranking Minority Member.

##### VI. PROXY VOTING

1. When a recorded vote is taken in the Committee on any bill, resolution, amendment, or any other question, a quorum being present, a Member who is unable to attend the meeting may submit her vote by proxy, in writing or by telephone, or through personal instructions. A proxy must be specific with respect to the matters it addresses and may not be counted either in reporting a matter, bill, or nomination to the floor, or in preventing any of the same from being reported to the floor.

##### VII. SUBCOMMITTEES

1. Any Member of the Committee may sit with any Subcommittee during its hearings or any other meeting, but shall not have the authority to vote on any matter before the Subcommittee unless she is a Member of such Subcommittee.

2. Subcommittees shall be considered de novo whenever there is a change in the Subcommittee chairmanship and seniority on the particular Subcommittee shall not necessarily apply.

3. Except for matters retained at the full Committee, matters shall be referred to the appropriate Subcommittee or Subcommittees by the Chairman, except as agreed by a majority vote of the Committee or by the agreement of the Chairman and the Ranking Minority Member.

4. Provided all Members of the Subcommittee consent, a bill or other matter may be polled out of the Subcommittee. In order to be polled out of a Subcommittee, a majority of the Members of the Subcommittee who vote, must vote in favor of reporting the bill or matter to the Committee.

##### VIII. ATTENDANCE RULES

1. Official attendance at all Committee markups and executive sessions of the Committee shall be kept by the Committee Clerk. Official attendance at all Subcommittee markups and executive sessions shall be kept by the Subcommittee Clerk.

2. Official attendance at all hearings shall be kept, provided that Senators are notified by the Committee Chairman and Ranking Minority Member, in the case of Committee hearings, and by the Subcommittee Chairman and Ranking Minority Member, in the case of Subcommittee hearings, 48 hours in advance of the hearing that attendance will be taken; otherwise, no attendance will be taken. Attendance at all hearings is encouraged.

#### NATIVE HAWAIIAN GOVERNMENT REORGANIZATION ACT OF 2005

Mr. AKAKA. Mr. President, for the past 6 years, I have worked with my colleagues in Hawaii's congressional delegation to enact legislation to extend the Federal policy of self-governance and self-determination to Native